Daily News

Frailty Classifications Associated With Prognosis Among Older Patients

Frailty Classifications Associated With Prognosis Among Older Patients

By

A comparison of frailty classifications of older patients with cancer was conducted to evaluate their performance in predicting outcomes.

Beach Umbrella Not Enough for Protection from UV Rays

Beach Umbrella Not Enough for Protection from UV Rays

By

Comparison studied the effectiveness of sun protection offered by a beach umbrella alone with that of sunscreen with a high sun protection factor.

Comprehensive Report Looks at Benefits and Harms of Medical Cannabis

Comprehensive Report Looks at Benefits and Harms of Medical Cannabis

Oral cannabinoids can ease chronic pain and chemotherapy-related nausea, but researchers cite risks, as well.

MABp1 Improves Symptoms vs Placebo in Colorectal Cancer

MABp1 Improves Symptoms vs Placebo in Colorectal Cancer

By

MABp1 (Xilonix) is an interleukin 1_-targeting antibody associated with antitumor activity and relief of debilitating symptoms in patients with advanced colorectal cancer. In this ongoing phase 3 clinical trial, its impact on other debilitating symptoms in this population was evaluated.

ASCO: Moderate Activity Linked to Longer Survival in Advanced CRC

ASCO: Moderate Activity Linked to Longer Survival in Advanced CRC

Moderate but not vigorous activity proved beneficial for patients with metastatic colorectal cancer.

Obesity Increases Risk for Transformation of MGUS to Multiple Myeloma

Obesity Increases Risk for Transformation of MGUS to Multiple Myeloma

By

Researchers sought to determine the influence of obesity on the transformation of MGUS, an asymptomatic plasma cell neoplasm, to multiple myeloma.

Excessive FDA Regulation Driving High Drug Prices

Excessive FDA Regulation Driving High Drug Prices

First-in-class drugs are fast-tracked while follow-on drugs can take up to 15 years to be approved by the FDA.

Lutetium-177 Dotatate Improves PFS in Advanced Midgut Carcinoid Tumors

Lutetium-177 Dotatate Improves PFS in Advanced Midgut Carcinoid Tumors

By

Findings are presented from an open-label NETTER-1 clinical trial evaluating the efficacy and safety of 177Lu-Dotatate in patients with advanced midgut neuroendocrine tumors who have experienced disease progression during first-line treatment with a somatostatin analogue.

Racial Disparities Persist in Myeloma Treatment Use

Racial Disparities Persist in Myeloma Treatment Use

By

Investigators found black patients with multiple myeloma are less likely to use newer, more advanced treatments such as autologous HSCT or bortezumib, and explored factors contributing to this as well as the impact on this population.

Ruxolitinib May Improve Symptom Control in Patients With CLL

Ruxolitinib May Improve Symptom Control in Patients With CLL

By

In this study, researchers evaluated whether ruxolitinib, a JAK2 inhibitor that reduces symptoms in patients with myelofibrosis, would improve disease-related symptoms in patients with CLL.

Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma

Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma

By

Researchers investigated whether VRd, which has demonstrated significant efficacy in newly diagnosed multiple myeloma, would improve outcomes in patients with previously untreated myeloma who are not planned for immediate ASCT.

3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma

3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma

By

Researchers report on an evaluation of the safety and preliminary efficacy of the HDAC6-selective inhibitor ricolinostat in combination with standard proteasome inhibitor therapy for relapsed or refractory multiple myeloma.

Lung Cancer Navigator App Aims to Help Patients Understand Disease

Lung Cancer Navigator App Aims to Help Patients Understand Disease

By

Lung Cancer Navigator, a mobile, customizable app from LUNGEVITY, helps patients with lung cancer better understand their disease, manage medications, track symptoms, and access support.

Cancer Mortality Rates Continue to Drop in the United States

Cancer Mortality Rates Continue to Drop in the United States

Cancer mortality rates in the United States have dropped, according to a new ACS report.

Menopause-specific QoL Changes Associated With Chemoprevention Nonadherence

Menopause-specific QoL Changes Associated With Chemoprevention Nonadherence

By

A cohort of participants in the MAP.3 trial completed the MENQOL questionnaire, and the findings shed light on the influence of changes in menopause-specific quality of life on aromatase inhibitor adherence in women at high risk for breast cancer.

Diarrhea Common But Manageable With Pertuzumab-containing Regimens

Diarrhea Common But Manageable With Pertuzumab-containing Regimens

By

Because treatment with pertuzumab could include adverse events similar to those observed with EGFR antagonists, such as diarrhea, researchers evaluated participants from 3 trials to determine the incidence and severity of diarrhea observed with pertuzumab.

Perceived Breast Density May Influence Single Read Suitability

Perceived Breast Density May Influence Single Read Suitability

Features mainly linked to mammographic breast density are key in influencing a classification of normal.

Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases

Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases

By

Results from a phase 3 trial comparing a 12-week dosing interval with the standard 4-week dosing interval of zoledronic acid to reduce the incidence of skeletal-related events and pain in patients with bone metastases.

Serum IL-12 May Predict for Chemotherapy-Related Fatigue in Early-Stage Breast Cancer

Serum IL-12 May Predict for Chemotherapy-Related Fatigue in Early-Stage Breast Cancer

By

In this study, researchers sought to identify physical, neurocognitive, and serologic markers that may correlate with self-reported fatigue before and after (neo)adjuvant chemotherapy for patients with early-stage breast cancer.

Considerable Shifts in NSCLC Treatment With Modest Gains in Survival

Considerable Shifts in NSCLC Treatment With Modest Gains in Survival

By

Investigators report on trends in treatment of advanced-stage NSCLC from 2000 to 2011, including impact on survival and total Medicare spending.

Cancer Cachexia Associated With Poor Outcomes

Cancer Cachexia Associated With Poor Outcomes

Findings at 6 and 12 months after treatment for advanced head and neck cancer indicate a higher risk of recurrences for those reporting cachexia after their treatment.

Adding Aprepitant Not Superior to Ondansetron Monotherapy for UA-RINV

Adding Aprepitant Not Superior to Ondansetron Monotherapy for UA-RINV

By

Many patients can still experience UA-RINV despite prophylactic therapy; therefore, researchers explored the effectiveness and safety of dual prophylactic therapy with an NK1 receptor antagonist and a 5-HT3 receptor antagonist.

Delayed Adjuvant Chemotherapy Not Associated With Survival in NSCLC

Delayed Adjuvant Chemotherapy Not Associated With Survival in NSCLC

By

Study evaluated differences in survival with respect to the time interval between tumor resection and initiation of postoperative chemotherapy in patients with NSCLC.

Tissue Factor May Predict for Recurrent VTE in Patients Receiving Anticoagulants

Tissue Factor May Predict for Recurrent VTE in Patients Receiving Anticoagulants

By

An evaluation of the association of tissue factor, clinical risk factors, and other biomarkers measured at the time of initial VTE with recurrent VTE helps determine their predictive value for patients at high risk.

Optimal Timing of Influenza Vaccination in Patients Receiving Chemotherapy

Optimal Timing of Influenza Vaccination in Patients Receiving Chemotherapy

By

A comparison of administering the influenza vaccine concurrently with chemotherapy with that of administration within the cytopenic period during 3-week chemotherapy cycles determined which schedule was the optimal timing for vaccination administration in this group.

Uric Acid May Mark Progression for Nasopharyngeal Cancer

Uric Acid May Mark Progression for Nasopharyngeal Cancer

High pretreatment uric acid may be a clinical biomarker for lung metastasis.

Patients With Breast Cancer Report More Cognitive Difficulties After Chemotherapy

Patients With Breast Cancer Report More Cognitive Difficulties After Chemotherapy

By

Researchers sought to evaluate the incidence of cancer-related cognitive impairment in patients with breast cancer in a large prospective, longitudinal, nationwide study. These findings address limitations in previous research.

O-DHAP and R-DHAP Equivalent As Salvage Therapy for R/R DLBCL

O-DHAP and R-DHAP Equivalent As Salvage Therapy for R/R DLBCL

By

Researchers sought to compare the efficacy of O-DHAP with R-DHAP as salvage treatment, followed by autologous hematopoietic cell transplantation.

New Oral Therapy Shows Promise Against Neurofibromatosis Type 1-Related Plexiform Neurofibromatomas in Children

New Oral Therapy Shows Promise Against Neurofibromatosis Type 1-Related Plexiform Neurofibromatomas in Children

By

In this clinical trial, researchers determined the safety and efficacy of selumetinib, a selective MEK inhibitor, in children with NF1-related neurofibromas.

Melanoma Incidence Still on the Rise in Parts of the United States

Melanoma Incidence Still on the Rise in Parts of the United States

Melanoma incidence varies by region, and many states have experienced an increase.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs